Skip to main content

Advertisement

Table 2 Efficacy and drug exposure

From: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Objective response rate; n (%) 65 (25.2)
Median duration of objective response, months 4.4 (95 %CI: 3.4–4.8)
Best overall response
 Complete response; n (%) 1 (0.4)
 Partial response; n (%) 64 (24.8)
 Stable disease (>6 months); n (%) 28 (10.9)
 Clinical benefit rate, % (95 %CI) 36.1 (30.2–42.2)
 Progressive disease; n (%) 157 (60.9)
 Not established; n (%) 8 (3.1)
 Median time to progression, months ( 95 %CI) 4 (3.3–4.3)
 Overall survival, months (95 %CI) 11.2 (9.3–12.1)
 One- year overall survival rate,% (95 %CI) 45.5 % (38.3–52.4)
 18-month overall survival rate, % (95 %CI) 23.1 % (16.3–30.6)
 2-year overall survival rate, % (95 %CI) 8.5 % (2.2–20.3)
Drug exposure
 Median EM cycles delivered; n (range) 5 (1–19)
 Dose reductions at initiation (%) 20.9
 Relative dose intensity (range) 0.92 (0.17–1.22)